Scaling of Cmin [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2014-11-27 14:47 (3434 d 20:35 ago) – Posting: # 13932
Views: 13,960

Hi Kumar,

❝ But I think for applying widening criteria we need to show CV>30% for reference product and the study should be reference replicate (3way or 4way).


Correct. I wouldn’t be too optimistic with the CVintra of 23.1% you reported.

❝ Can we use Pre-dose concentration and Ctau of steady state to show variability?:confused:


This idea was discussed in Bonn last year. Members of EMA’s PKWP seemed to be happy with it. I guess the MR-GL was adopted at EMA’s CHMP-meeting last week. Let’s wait for it (and the comments). The analysis is a little bit tricky* because the replicates originate from the same period.



Edit: The MR-GL was adopted indeed. See here.

Edit: GL, Section 6.8.2.2:

Any widening of the acceptance criteria for Cmax should follow the recom­men­da­tions on highly variable drug products in the Guideline on the Investigation of Bio­equivalence (CPMP/EWP/QWP/1401/98).
A similar approach can be used for widening the acceptance criteria for Cmax,ss, Cτ,ss, and partialAUC. Calculation of the intra-subject variability in multiple dose studies can be based on two consecutive administrations of the same product after reaching steady state.


Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,990 posts in 4,826 threads, 1,664 registered users;
49 visitors (1 registered, 48 guests [including 2 identified bots]).
Forum time: 12:22 CEST (Europe/Vienna)

If you don’t like something change it;
if you can’t change it, change the way you think about it.    Mary Engelbreit

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5